{"id":"NCT00917267","sponsor":"AstraZeneca","briefTitle":"A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects","officialTitle":"A Comparator-Controlled Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control (HbA1c) and Safety in Asian Subjects With Type 2 Diabetes Mellitus Managed With Oral Antidiabetic Medications","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-07","primaryCompletion":"2010-09","completion":"2011-04","firstPosted":"2009-06-10","resultsPosted":"2012-12-31","lastUpdate":"2015-04-09"},"enrollment":691,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"exenatide once weekly","otherNames":[]},{"type":"DRUG","name":"exenatide twice daily","otherNames":["Byetta"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"Previous studies have suggested that a once-weekly formulation of exenatide may provide sustained glycemic control. These previous studies of exenatide once weekly have been conducted in non-Asian populations, so this study has been developed to support the local regulatory requirements of China, Korea, Japan, India, and Taiwan.","primaryOutcome":{"measure":"Change in HbA1c From Baseline to Week 26.","timeFrame":"Baseline, Week 26","effectByArm":[{"arm":"Exenatide Once Weekly","deltaMin":-1.43,"sd":0.07},{"arm":"Exenatide Twice Daily","deltaMin":-1.12,"sd":0.07}],"pValues":[{"comp":"OG000 vs OG001","p":"<.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":42,"countries":["China","India","Japan","South Korea","Taiwan"]},"refs":{"pmids":["24843650","24843631"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":340},"commonTop":["Nausea","Vomiting","Diarrhoea","Dyslipidaemia","Constipation"]}}